Virus-mimetic nanovesicles as a versatile antigen-delivery system

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 45, 2015, Pages E6129-E6138

  Zhang, Pengfei ^a   Chen, Yixin ^a   Zeng, Yun ^a,b   Shen, Chenguang ^a   Li, Rui ^a   Guo, Zhide ^a   Li, Shaowei ^a   Zheng, Qingbing ^a   Chu, Chengchao ^a   Wang, Zhantong ^a,c   Zheng, Zizheng ^a   Tian, Rui ^a   Ge, Shengxiang ^a   Zhang, Xianzhong ^a   Xia, Ning Shao ^a   Liu, Gang ^a   Chen, Xiaoyuan ^a  

^a XIAMEN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GLYCOPROTEIN; HUMAN PAPILLOMAVIRUS L2 EPITOPE PEPTIDE; NANOCARRIER; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS MIMETIC NANOVESICLE; WART VIRUS VACCINE; ANTIGEN; NANOMATERIAL; PHOSPHOLIPID; RECOMBINANT PROTEIN; SURFACTANT; VIRUS VACCINE;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; ENDOPLASMIC RETICULUM; FEMALE; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; MEMBRANE VESICLE; MOLECULAR WEIGHT; MOUSE; NANOBIOTECHNOLOGY; NANOFABRICATION; NANOPHARMACEUTICS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RENAL CLEARANCE; TRANSPORT VESICLE; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; NANOTECHNOLOGY; PROCEDURES; TRENDS;

ANTIGENS; DRUG DELIVERY SYSTEMS; NANOSTRUCTURES; NANOTECHNOLOGY; PHOSPHOLIPIDS; RECOMBINANT PROTEINS; SURFACE-ACTIVE AGENTS; TRANSPORT VESICLES; VIRAL VACCINES;

EID: 84946728027     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1505799112     Document Type: Article

References (32)

1. Smith DM, Simon JK, Baker JR, Jr (2013) Applications of nanotechnology for immunology. Nat Rev Immunol 13(8):592-605.
2. Théry C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9(8):581-593.
3. Hu CMJ, Fang RH, Luk BT, Zhang L (2013) Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol 8(12):933-938.
4. Ulmer JB, Valley U, Rappuoli R (2006) Vaccine manufacturing: Challenges and solutions. Nat Biotechnol 24(11):1377-1383.
5. Pitoiset F, Vazquez T, Bellier B (2015) Enveloped virus-like particle platforms: Vaccines of the future? Expert Rev Vaccines 14(7):913-915.
6. Chen DJ, et al. (2010) Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci USA 107(7):3099-3104.
7. Yoo JW, Irvine DJ, Discher DE, Mitragotri S (2011) Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 10(7):521-535.
8. Dobrovolskaia MA, McNeil SE (2007) Immunological properties of engineered nanomaterials. Nat Nanotechnol 2(8):469-478.
9. Fang RH, et al. (2014) Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett 14(4):2181-2188.
10. Zhao Q, Li S, Yu H, Xia N, Modis Y (2013) Virus-like particle-based human vaccines: Quality assessment based on structural and functional properties. Trends Biotechnol 31(11):654-663.
11. Wolfers J, et al. (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7(3):297-303.
12. Parodi A, et al. (2013) Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol 8(1):61-68.
13. Hegde RS, Bernstein HD (2006) The surprising complexity of signal sequences. Trends Biochem Sci 31(10):563-571.
14. Hildebrand A, Neubert R, Garidel P, Blume A (2002) Bile salt induced solubilization of synthetic phosphatidylcholine vesicles studied by isothermal titration calorimetry. Langmuir 18(7):2836-2847.
15. Ross BP, et al. (2004) Micellar aggregation and membrane partitioning of bile salts, fatty acids, sodium dodecyl sulfate, and sugar-conjugated fatty acids: Correlation with hemolytic potency and implications for drug delivery. Mol Pharm 1(3):233-245.
16. Garidel P, Hildebrand A, Knauf K, Blume A (2007) Membranolytic activity of bile salts: Influence of biological membrane properties and composition. Molecules 12(10): 2292-2326.
17. Balzac F, et al. (1993) Expression and functional analysis of a cytoplasmic domain variant of the beta 1 integrin subunit. J Cell Biol 121(1):171-178.
18. Gambhira R, et al. (2007) A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81(24):13927-13931.
19. Copeland CS, Doms RW, Bolzau EM, Webster RG, Helenius A (1986) Assembly of influenza hemagglutinin trimers and its role in intracellular transport. J Cell Biol 103(4):1179-1191.
20. Yang L, et al. (2012) HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: A desirable vaccine component. J Virol 86(14):7662-7676.
21. Jagu S, et al. (2009) Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 101(11):782-792.
22. Li ZB, Chen X (2009) MicroPET, MicroSPECT, and NIR fluorescence imaging of biomolecules in vivo. Methods Mol Biol 544:461-481.
23. Bronte V, Pittet MJ (2013) The spleen in local and systemic regulation of immunity. Immunity 39(5):806-818.
24. Barral P, Sánchez-Niño MD, van Rooijen N, Cerundolo V, Batista FD (2012) The location of splenic NKT cells favours their rapid activation by blood-borne antigen. EMBO J 31(10):2378-2390.
25. Ceriotti A, Colman A (1990) Trimer formation determines the rate of influenza virus haemagglutinin transport in the early stages of secretion in Xenopus oocytes. J Cell Biol 111(2):409-420.
26. Kaaijk P, et al. (2013) Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine 31(7):1065-1071.
27. Shi J, et al. (2014) Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes. Proc Natl Acad Sci USA 111(28):10131-10136.
28. Yuan Q, et al. (2011) Differential diagnosis of pandemic (H1N1) 2009 infection by detection of haemagglutinin with an enzyme-linked immunoassay. Clin Microbiol Infect 17(10):1574-1580.
29. Chen Y, et al. (2009) Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis 199(1):49-58.
30. Chen Y, et al. (2011) Serological survey of antibodies to influenza A viruses in a group of people without a history of influenza vaccination. Clin Microbiol Infect 17(9): 1347-1349.
31. He R, et al. (2014) Facile synthesis of pentacle gold-copper alloy nanocrystals and their plasmonic and catalytic properties. Nat Commun 5:4327.
32. Song XR, et al. (2015) Co9 se8 nanoplates as a new theranostic platform for photoacoustic/magnetic resonance dual-modal-imaging-guided chemo-photothermal combination therapy. Adv Mater 27(21):3285-3291.